Literature DB >> 2674208

Drug delivery systems. 1. site-specific drug delivery using liposomes as carriers.

V V Ranade1.   

Abstract

Drug delivery systems, offering controlled delivery of biologically active agents, are rapidly gaining importance in pharmaceutical research and development. To achieve controlled drug delivery, i.e., the administration of drugs so that optimal amount reaches the target site to cure or control the disease state, increasingly sophisticated systems containing different carriers have been developed. Macromolecules represent one of the carriers involved, and they have taken on a significantly prominent role in various modes of administration of therapeutic agents. Among macromolecules, for example, synthetic copolymers, polysaccharides, liposomes, polyanions and antibodies, as drug carriers, liposomes have proved most effective for diseases affecting the reticuloendothelial system and blood cells in particular. Liposomes, which are vesicles consisting of one or more concentrically ordered assemblies of phospholipids bilayers, range in size from a nanometer to several micrometers. Phospholipids such as egg phosphatidylcholine, phosphatidylserine, synthetic dipalmitoyl-DL-alpha-phosphatidylcholine or phosphatidylinositol, have been used in conjunction with cholesterol and positively or negatively charged amphiphiles such as stearylamine or phosphatidic acid. Alteration of surface charge has been shown to enhance drug incorporation and also influence drug release. Because of the multifold characteristics as drug carriers, liposomes have been investigated extensively as carriers of anticancer agents for the past several years. Liposomal entrapments include a variety of pharmacologically active compounds such as antimalarial, antiviral, anti-inflammatory and anti-fungal agents as well as antibiotics, prostaglandins, steroids and bronchodilators to name a few. The liposomal entrapment has been shown to have considerable effect on the pharmacokinetics and tissue distribution of administered drugs. Despite the potential value of liposomes as unique carriers, the major obstacles are the first order targeting of a systemically given liposomes, physical stability and manufacture of the liposomal products and these problems still remain to be overcome. Drug delivery systems evolving in the 1980s have become increasingly dependent on fundamental cell-biology and receptor-mediated endocytotic mechanisms. Drug delivery systems during the 1990s may take advantage of the specificity of receptor-mediated uptake mechanisms as well as polymer chemistry and cell-biology in order to introduce more precise and efficient target-specific delivery systems that are based especially on the liposome technology.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2674208     DOI: 10.1002/j.1552-4604.1989.tb03403.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

1.  High technology drugs for cancer: the decision process for adding to a formulary.

Authors:  J L Glennie; D M Woloschuk; K W Hall
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

2.  Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis.

Authors:  C P Leamon; P S Low
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

Review 3.  Liposomal drug delivery. Advantages and limitations from a clinical pharmacokinetic and therapeutic perspective.

Authors:  R M Fielding
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

4.  Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer.

Authors:  Hong Luo; Qian Zhong; Li-juan Chen; Xiao-rong Qi; A-fu Fu; Han-shuo Yang; Fan Yang; Hong-gang Lin; Yu-quan Wei; Xia Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2008-03-19       Impact factor: 4.553

5.  Plasma concentrations of bupivacaine after brachial plexus administration of liposome-associated and plain solutions to rabbits.

Authors:  J G Boogaerts; N D Lafont; H Luo; F J Legros
Journal:  Can J Anaesth       Date:  1993-12       Impact factor: 5.063

6.  Synergistic antitumor effects of liposomal honokiol combined with cisplatin in colon cancer models.

Authors:  Niang Cheng; Tian Xia; Ying Han; Qing Jun He; Rong Zhao; Jun Rong Ma
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

7.  Renal selective N-acetyl-L-gamma-glutamyl prodrugs: studies on the selectivity of some model prodrugs.

Authors:  J C Drieman; H H Thijssen; H A Struyker-Boudier
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

8.  Liposome bupivacaine for pain control after total knee arthroplasty: a meta-analysis.

Authors:  Zhong Qing Wu; Ji Kang Min; Dan Wang; Yong Jian Yuan; Heng Li
Journal:  J Orthop Surg Res       Date:  2016-07-22       Impact factor: 2.359

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.